Biomarker study in kidney disease caused by IgA
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at lab markers (“biomarkers”) in people with IgA nephropathy, using kidney biopsy tissue. It may help researchers find better ways to understand the disease and tailor future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 14 or older.
- You have a kidney diagnosis confirmed by biopsy: primary IgA nephropathy.
- Your biopsy sample includes at least 10 kidney filtering units (glomeruli) for review.
- Your first kidney biopsy was done within the last 3 years.
- Your kidney filtering function is preserved (eGFR is 60 or higher).
- You (or your parent/legal representative) can understand the study and sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This study looks at a specific type of antibody called IgA in patients with certain kidney diseases. It aims to understand which IgA antibodies cause kidney damage, which could help develop better treatments.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.